摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-allyl-4-bromo-6-methoxyphenol | 352019-92-2

中文名称
——
中文别名
——
英文名称
2-allyl-4-bromo-6-methoxyphenol
英文别名
4-bromo-2-methoxy-6-prop-2-enylphenol
2-allyl-4-bromo-6-methoxyphenol化学式
CAS
352019-92-2
化学式
C10H11BrO2
mdl
——
分子量
243.1
InChiKey
MUVHSMQYFKENTR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    298.8±35.0 °C(Predicted)
  • 密度:
    1.409±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Triazolone derivatives
    申请人:Clark Richard
    公开号:US20080015199A1
    公开(公告)日:2008-01-17
    A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]
    以下一般式(1)表示的化合物,其盐或上述化合物的水合物是一种新型化合物,可用于治疗和/或预防与血栓形成相关的疾病,并且具有适当的物理化学稳定性,更安全。 [其中R1a,R1b,R1c和R1d分别独立表示氢等;R2表示可选择取代的苯基等;R3表示可选择取代的C6-10芳基等;Z1和Z2分别独立表示氢]
  • Investigating the microwave-accelerated Claisen rearrangement of allyl aryl ethers: Scope of the catalysts, solvents, temperatures, and substrates
    作者:Zi Hui、Songwei Jiang、Xiang Qi、Xiang-Yang Ye、Tian Xie
    DOI:10.1016/j.tetlet.2020.151995
    日期:2020.6
    The microwave-accelerated Claisen rearrangement of allyl aryl ethers was investigated, in order to gain insight into the scope of the catalysts, solvents, temperatures, and substrates. Among the catalysts examined, phosphomolybdic acid (PMA) was found to greatly accelerate the reaction in NMP, at temperatures ranging from 220 to 300 °C. This method was found to be useful for preparing several intermediates
    对微波加速烯丙基芳基醚的克莱森重排进行了研究,以便深入了解催化剂,溶剂,温度和底物的范围。在所考察的催化剂中,发现磷钼酸(PMA)在220至300°C的温度下可大大促进NMP中的反应。发现该方法对于使用贵金属催化剂例如Au(I),Ag(I)和Pt(II)制备先前在文献中报道的几种中间体是有用的。另外,在芳基部分带有溴和硝基的底物需要仔细调整反应条件,以避免复杂的产物分布。
  • TRIAZOLONE DERIVATIVES
    申请人:CLARK Richard
    公开号:US20100190783A1
    公开(公告)日:2010-07-29
    A Compound represented by the following general formula (1): wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen or salts thereof or hydrates of the foregoing.
    以下是通式(1)表示的化合物:其中R1a,R1b,R1c和R1d各自独立地表示氢等;R2表示可选取代的苯基等;R3表示可选取代的C6-10芳基等;Z1和Z2各自独立地表示氢或其盐或其水合物。
  • Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
    申请人:KARYOPHARM THERAPEUTICS INC.
    公开号:US20160221994A1
    公开(公告)日:2016-08-04
    The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
    本发明通常涉及取代的2,3-二氢苯并呋喃基化合物,更具体地涉及由结构式(I)表示的化合物,或其药学上可接受的盐,在此变量的定义和描述中。本发明还包括合成和使用结构式(I)的化合物,或其药学上可接受的盐或组合物,例如在治疗癌症(例如曼托细胞淋巴瘤)和其他疾病和障碍中。
  • TRIAZOLONE DERIVATIVE
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP2000465A1
    公开(公告)日:2008-12-10
    A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R1a, R1b, R1c and R1d each independently represent hydrogen, etc.; R2 represents optionally substituted phenyl, etc.; R3 represents optionally substituted C6-10 aryl, etc.; and Z1 and Z2 each independently represent hydrogen]
    由以下通式(1)代表的化合物、其盐类或前述化合物的水合物是一种新型化合物,可用于治疗和/或预防与血栓形成有关的疾病,且具有较高的安全性和适当的理化稳定性。 [其中 R1a、R1b、R1c 和 R1d 各自独立地代表氢等;R2 代表任选取代的苯基等;R3 代表任选取代的 C6-10 芳基等;Z1 和 Z2 各自独立地代表氢]
查看更多